Tech Transfer eNews Blog

Kansas State licenses out novel treatment for deadly cat disease

By Jesse Schwartz
Published: September 26th, 2018

Kansas State University and Anivive Lifesciences, a California-based developer of pet care solutions, have entered into a license agreement to commercialize a treatment for a viral cat disease.

Feline infectious peritonitis (FIP) is a progressive and fatal disease that can affect both domestic and wild cats. Kansas State researchers Yunjeong Kim and Kyeong-Ok Chang, in collaboration with Wichita State University chemist William Groutas, have developed the antiviral compound GC376 to serve as the first effective treatment for FIP.

“We have been working on antiviral drugs that inhibit a specific virus protease of some important human and animal viruses, and we were able to make very potent inhibitors of FIP,” says Kim. “Licensing our compound to Anivive Lifesciences is a huge step forward in transitioning our research to commercialization to make this treatment available to the public.”

Kansas State’s Institute for Commercialization negotiated the licensing deal with Anivive and will work with the company to accelerate GC376 toward FDA approval and commercialization.

“The team members from Anivive Lifesciences are committed to developing the compound GC376 for the treatment of FIP with a sense of urgency, and we look forward to watching their progress over the coming years,” says Bret Ford, associate director for licensing at the Institute for Commercialization.

Dylan Balsz, founder and CEO of Anivive, comments, “FIP has long plagued veterinarians and pet owners alike, and we look forward to moving this program toward an eventual approval.”

Source: Feedstuffs

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment